Gilead Sciences (NASDAQ: GILD) acquires privately-held bio-tech firm Calistoga Pharmaceuticals for $ 375 million. Calistoga stands to earn an additional $ 225 million if certain milestones are achieved. Gilead will consummate the transaction with cash on hand.
Gilead will pick up a stable of cancer fighting compounds, including Calistoga's lead product candidate, CAL-101, a "first-in-class specific inhibitor of the PI3K delta isoform. PI3K delta is preferentially expressed in leukocytes involved in a variety of inflammatory and autoimmune diseases and hematological cancers. CAL-101 is currently in Phase II studies as a single agent in patients with refractory indolent non-Hodgkin's lymphoma (iNHL) and in combination with rituximab in treatment-naïve elderly patients with chronic lymphocytic leukemia (CLL). In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors that are in preclinical development, and may have application in both oncology and inflammatory diseases."
Advisors to the transaction:
"Calistoga Pharmaceuticals' exclusive financial advisor for the transaction was J.P. Morgan Securities LLC while Wilson Sonsini Goodrich & Rosati, P.C. was its legal advisor."
The full press release is: here
Showing posts with label gild. Show all posts
Showing posts with label gild. Show all posts
Wednesday, February 23, 2011
Friday, February 18, 2011
Gilead Sciences says Natco Pharma is challenging patent for Tamiflu
Gilead Sciences (GILD) says that Natco Pharma is challenging its patent for the influenza drug "Tamiflu" calling it invalid.
Natco is seeking to offer a generic version of Tamiflu.
According to the report on Bloomberg:
"Gilead Sciences Inc. (GILD) said Monday that Natco Pharma Ltd. is challenging a patent on the flu drug Tamiflu.
Tamiflu was developed by Gilead, which receives royalties on the drug's sale from Roche Holding AG.
Gilead said Natco is seeking Food and Drug Administration approval to sell a generic version of Tamiflu and alleges that Gilead's patent on the drug is invalid.
Gilead said it is reviewing the notice it received from the FDA and has 45 days to file a lawsuit against Natco. If it does sue Natco, that would bar the FDA from allowing Natco to make the Tamiflu generic for two and half years or until the case is decided in Natco's favor, Gilead said."
http://www.bloomberg.com/news/2011-02-07/gilead-reports-patent-challenge-on-tamiflu.html
Natco is seeking to offer a generic version of Tamiflu.
According to the report on Bloomberg:
"Gilead Sciences Inc. (GILD) said Monday that Natco Pharma Ltd. is challenging a patent on the flu drug Tamiflu.
Tamiflu was developed by Gilead, which receives royalties on the drug's sale from Roche Holding AG.
Gilead said Natco is seeking Food and Drug Administration approval to sell a generic version of Tamiflu and alleges that Gilead's patent on the drug is invalid.
Gilead said it is reviewing the notice it received from the FDA and has 45 days to file a lawsuit against Natco. If it does sue Natco, that would bar the FDA from allowing Natco to make the Tamiflu generic for two and half years or until the case is decided in Natco's favor, Gilead said."
http://www.bloomberg.com/news/2011-02-07/gilead-reports-patent-challenge-on-tamiflu.html
Subscribe to:
Posts (Atom)